Question special

I am not a neurologist thus don't routinely take care of this patient group. Are the baseline characteristics of patients having a stroke in the US similar to this study? Can you comment more on the generalizability of the results to our patients in the US? What issues do you foresee in the generalizability of this trial?

How is the trial affected by the biased introduced using open-label trial and not including a placebo infusion to EVT only group?

Thank you for your time in answering our questions.